<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="913">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149261</url>
  </required_header>
  <id_info>
    <org_study_id>SAACOAG</org_study_id>
    <nct_id>NCT05149261</nct_id>
  </id_info>
  <brief_title>Coagulopathy in Acute Aortic Syndrome</brief_title>
  <acronym>SAACAOG</acronym>
  <official_title>Coagulopathy in Acute Aortic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Georges Pompidou Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The existence of AAS coagulopathy has been reported, related to blood contact with the walls&#xD;
      of the non-endothelialized false lumens. It is likely that endothelial dysfunction generated&#xD;
      by vascular lesions may largely contribute to the development of coagulopathy, such as&#xD;
      described in trauma-induced coagulopathy. This endotheliopathy of the AAS has never been&#xD;
      evaluated. The coagulopathy of AAS and more specifically the endotheliopathy are poorly&#xD;
      described and therefore have no standardized treatment.&#xD;
&#xD;
      The main objective of this study is to describe the coagulopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute aortic syndromes (AAS) result from an organic lesion of the aortic wall. The various&#xD;
      symptoms of AAS, mainly the acute chest pain, leads to a breakdown of the intima or the media&#xD;
      of the aorta. This syndrome is made of three entities : aortic dissection (DA), intra-mural&#xD;
      hematoma (HIM) and penetrating atherosclerotic ulcer (PAU). Surgery is a complex emergency&#xD;
      treatment of choice. Patients suffering from these pathologies die mainly from hemorrhagic&#xD;
      shock due to haemostasis disorders, which requires massive transfusion. The existence of AAS&#xD;
      coagulopathy has been reported, related to blood contact with the walls of the&#xD;
      non-endothelialized false lumens. It is likely that endothelial dysfunction generated by&#xD;
      vascular lesions may largely contribute to the development of coagulopathy, such as described&#xD;
      in trauma-induced coagulopathy. This endotheliopathy of the AAS has never been evaluated. The&#xD;
      coagulopathy of AAS and more specifically the endotheliopathy are poorly described and&#xD;
      therefore have no standardized treatment.&#xD;
&#xD;
      The main objective of this study is to describe the coagulopathy and more specifically the&#xD;
      endotheliopathy of AAS, in particular assessing coagulation disorders, hyperactivation of&#xD;
      fibrinolysis, quantitative or functional platelets disorder and endotheliopathy. The&#xD;
      secondary objective is to determine the factors associated with this coagulopathy. This&#xD;
      includes 1 / assessment of potential risk factors for coagulopathy, 2 / the prognosis of&#xD;
      coagulopathy by assessing the relationship between coagulopathy and transfusion requirements&#xD;
      and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>total transfusion requirements</measure>
    <time_frame>Day 2</time_frame>
    <description>red blood cells units (number)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>death from AAS</measure>
    <time_frame>Day 30</time_frame>
    <description>probability of Survival (pourcentage %)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>coagulopathy rTQ &gt; 1.2 incidence</measure>
    <time_frame>baseline</time_frame>
    <description>pourcentage %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total transfusion requirements</measure>
    <time_frame>Day 1</time_frame>
    <description>red blood cell unit, fresh frozen plasma and platelets units (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total transfusion requirements</measure>
    <time_frame>Day 2</time_frame>
    <description>red blood cell unit, fresh frozen plasma and platelets units (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total transfusion requirements</measure>
    <time_frame>Day 3</time_frame>
    <description>red blood cell unit, fresh frozen plasma and platelets units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total transfusion requirements</measure>
    <time_frame>Day 7</time_frame>
    <description>red blood cell unit, fresh frozen plasma and platelets units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : coagulation factors consumption</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 7</time_frame>
    <description>pourcentage %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : coagulation factors consumption</measure>
    <time_frame>Day 2</time_frame>
    <description>pourcentage %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : coagulation factors consumption</measure>
    <time_frame>Day 3</time_frame>
    <description>pourcentage %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : coagulation factors consumption</measure>
    <time_frame>Day 7</time_frame>
    <description>pourcentage %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : fibrinolysis D-dimers</measure>
    <time_frame>Day 1</time_frame>
    <description>µg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : fibrinolysis D-dimers</measure>
    <time_frame>Day 2</time_frame>
    <description>µg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : fibrinolysis D-dimers</measure>
    <time_frame>Day 3</time_frame>
    <description>µg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological AAS coagulopathy : fibrinolysis D-dimers</measure>
    <time_frame>Day 7</time_frame>
    <description>µg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalisation duration</measure>
    <time_frame>hospital discharge</time_frame>
    <description>number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of misdiagnosis and misdiagnosis-induced treatments</measure>
    <time_frame>Day 2</time_frame>
    <description>massive post-operative bleeding (BART definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of misdiagnosis and misdiagnosis-induced treatments</measure>
    <time_frame>Day 7</time_frame>
    <description>massive post-operative bleeding (BART definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets dysfunction</measure>
    <time_frame>day 1</time_frame>
    <description>platelets rate G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets dysfunction</measure>
    <time_frame>day 2</time_frame>
    <description>platelets rate G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets dysfunction</measure>
    <time_frame>day 3</time_frame>
    <description>platelets rate G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets dysfunction</measure>
    <time_frame>day 7</time_frame>
    <description>platelets rate G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelets dysfunction</measure>
    <time_frame>baseline</time_frame>
    <description>CD 40 L pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>IL6 rate pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>IL8 rate pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>syndecan rate pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>endocan rate pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>angiopoietine 2 rate ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>angiopoietine 2 / angiopoietine 2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>VEGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotheliopathy</measure>
    <time_frame>baseline</time_frame>
    <description>FGF basic ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptoms-surgery delay</measure>
    <time_frame>baseline</time_frame>
    <description>time hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical severity shock</measure>
    <time_frame>baseline</time_frame>
    <description>acidosis pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical severity shock</measure>
    <time_frame>baseline</time_frame>
    <description>lactate level (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical severity shock</measure>
    <time_frame>baseline</time_frame>
    <description>number of organs with malperfusion (number)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coagulopathy</condition>
  <arm_group>
    <arm_group_label>Acute aortic syndrome</arm_group_label>
    <description>patients admitted to the Georges Pompidou European Hospital via the &quot;SOS aorta&quot; network</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Routine care blood samples will be taken at different moments of the hospital stay&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The EGPH offers, since 2009, a multidisciplinary network called &quot;SOS Aorta&quot; to centralize&#xD;
        clinico-radiological suspicions of acute aortic syndrome in Ile de France and provide&#xD;
        responsive and accessible medico-surgical care permanently. We included prospectively and&#xD;
        analysed retrospectively (descripive study) all patient aged more than 18y who were&#xD;
        admitted at EGPH for AAS suspicion via SOS Aorta Network.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admitted to hospital via the &quot;SOS Aorta&quot; network for acute aortic syndrome (AAS)&#xD;
             suspicion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aged &lt; 18y&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  no social security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Diane Zlotnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Georges Pompidou Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Godier, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>European Georges Pompidou Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Zlotnik, MD</last_name>
    <phone>+33156092428</phone>
    <email>diane.zlotnik@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Godier, MD-PhD</last_name>
    <phone>+33156092584</phone>
    <email>anne.godier@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Godier, MD-PhD</last_name>
      <phone>+33156092584</phone>
      <email>anne.godier@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>European Georges Pompidou Hospital</investigator_affiliation>
    <investigator_full_name>Diane Zlotnik</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coagulopathy</keyword>
  <keyword>Acute aortic dissection</keyword>
  <keyword>Blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>we will maybe try later to make a multicentric descriptive analysis with other french hospitals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

